IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population

Journal of Digestive Diseases

Volumn 16, Issue 2, 2015, Pages 90-97

  Dong, Zhi Xia ^a   Zhou, Hui Juan ^a   Xiang, Xiao Gang ^a   Guo, Si Min ^a   Zhuang, Yan ^a   Zhao, Gang De ^a   Xie, Qing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chronic hepatitis C; Human IL28B protein; Rapid virological response; Single nucleotide polymorphism; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENDER; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAN CHINESE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IL28B GENE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; PERSISTENT INFECTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS TRANSMISSION; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHINA; DRUG COMBINATION; DRUG EFFECTS; ETHNOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; STATISTICAL MODEL;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84923292349     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12202     Document Type: Article

References (34)

1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S21-29.
2. Burra P. Hepatitis C. Semin Liver Dis 2009; 29: 53-65.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
4. World Health Organization. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. Geneva: WHO Press, 2014.
5. Chinese Society of Hepatology, Society of Infectious Diseases, Chinese Medical Association. Guideline of prevention and treatment of hepatitis C. Chin J Infect Dis 2004; 22: 131-136 (in Chinese).
6. National Institutes of Health. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.
7. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
8. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
9. Hadziyannis SJ, Sette H Jr, Morgan TR etal.; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
10. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
11. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
13. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
14. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004; 39: 880-890.
15. Tang J, Kaslow RA. Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection. Pharmacogenomics J 2004; 4: 171-174.
16. Thomas DL, Astemborski J, Rai RM etal. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456.
17. Ank N, Paludan SR. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors 2009; 35: 82-87.
18. Li M, Liu X, Zhou Y, Su SB. Interferon-λs: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86: 23-32.
19. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-3854.
20. Marcello T, Grakoui A, Barba-Spaeth G etal. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898.
21. Chen JY, Lin CY, Wang CM etal. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun 2011; 12: 300-309.
22. Stättermayer AF, Stauber R, Hofer H etal. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-350.e2.
23. Urban TJ, Thompson AJ, Bradrick SS etal. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896.
24. Tillmann HL, Thompson AJ, Patel K etal.; German Anti-D Study Group. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-1921.
25. McCarthy JJ, Li JH, Thompson A etal. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
26. Montes-Cano MA, García-Lozano JR, Abad-Molina C etal. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-37.
27. Mangia A, Thompson AJ, Santoro R etal. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.e1.
28. Abe H, Ochi H, Maekawa T etal. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-443.
29. Aparicio E, Parera M, Franco S etal. IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 2010; 5: e13771.
30. Grebely J, Petoumenos K, Hellard M etal.; ATAHC Study Group. Potential role for IL28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 1216-1224.
31. Rauch A, Kutalik Z, Descombes P etal.; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.e7.
32. Yu ML, Dai CY, Huang JF etal. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-1893.
33. D'Ambrosio R, Aghemo A, De Francesco R etal. The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. Int J Mol Sci 2014; 15: 7213-7224.
34. Indolfi G, Azzari C, Resti M. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children. World J Gastroenterol 2014; 20: 9245-9252.